Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.34
USD
|
-0.01%
|
|
+1.89%
|
-4.29%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9.251
|
11.03
|
21.95
|
8.253
|
4.465
|
4.325
|
-
|
-
|
Enterprise Value (EV)
1 |
9.251
|
11.03
|
21.95
|
8.253
|
4.465
|
4.325
|
4.325
|
4.325
|
P/E ratio
|
-2.7
x
|
-0.58
x
|
-1.3
x
|
-0.81
x
|
-0.45
x
|
-0.65
x
|
-1.3
x
|
-1.64
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-3,714,758
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-3,311,755
x
|
-
|
-3,575,023
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
228
|
1,007
|
2,820
|
2,856
|
3,189
|
3,228
|
-
|
-
|
Reference price
2 |
40.50
|
10.95
|
7.785
|
2.890
|
1.400
|
1.340
|
1.340
|
1.340
|
Announcement Date
|
11/25/19
|
11/4/20
|
11/29/21
|
3/31/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-5.91
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.21
|
-4.686
|
-7.441
|
-10.29
|
-9.93
|
-14.44
|
-18.36
|
-26.09
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.172
|
-4.655
|
-7.437
|
-10.08
|
-9.289
|
-14.44
|
-18.36
|
-26.09
|
Net income
1 |
-2.172
|
-4.655
|
-7.437
|
-10.08
|
-9.289
|
-14.44
|
-18.36
|
-26.09
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-15.00
|
-18.90
|
-6.000
|
-3.560
|
-3.140
|
-2.070
|
-1.030
|
-0.8150
|
Free Cash Flow
|
-2.793
|
-
|
-6.141
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/25/19
|
11/4/20
|
11/29/21
|
3/31/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.251
|
-1.887
|
-
|
-2.471
|
-2.394
|
-3.476
|
-2.292
|
-1.784
|
-2.614
|
-3.24
|
-3.41
|
-3.556
|
-3.66
|
-3.816
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.25
|
-1.887
|
-
|
-2.449
|
-2.33
|
-3.339
|
-2.168
|
-1.599
|
-2.449
|
-3.073
|
-3.41
|
-3.556
|
-3.66
|
-3.816
|
Net income
1 |
-2.25
|
-1.887
|
-1.965
|
-2.449
|
-2.33
|
-3.339
|
-2.168
|
-1.599
|
-2.449
|
-3.073
|
-3.41
|
-3.556
|
-3.66
|
-3.816
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.500
|
-1.050
|
-0.7500
|
-0.9000
|
-0.8200
|
-1.180
|
-0.7600
|
-0.5600
|
-0.8300
|
-0.9900
|
-1.055
|
-0.7350
|
-0.5650
|
-0.3200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/12/21
|
11/29/21
|
5/12/22
|
8/9/22
|
11/8/22
|
3/31/23
|
5/11/23
|
8/10/23
|
11/13/23
|
3/25/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-2.79
|
-
|
-6.14
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/25/19
|
11/4/20
|
11/29/21
|
3/31/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
1.34
USD Average target price
16.67
USD Spread / Average Target +1,143.87% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.29% | 4.32M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|